Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
Background: Lopinavir/ritonavir (LPV/r) is a major antiretroviral treatment in China, but little is known about the performance of first-line LPV/r-based regimen in treatment-naïve patients with human immunodeficiency virus type 1 (HIV-1) infection. This study aims to assess the efficacy and adverse effect events of LPV/r plus lamivudine and tenofovir or zidovudine as an initial antiretroviral treatment in HIV-1-infected individuals for whom cannot take efavirenz (EFV) or is allergic to EFV.Methods: We performed a retrospective study of patients registering with the China’s National Free Antiretroviral Treatment Program from July 2012 to January 2017, followed at a tertiary care hospital in Beijing, China. The primary outcome was the proportion of subjects with HIV-1 RNA ≤40 copies/ml at 6 and 24 months of treatment. We assessed the immunological response and adverse events.Results: In total, 4,862 patients were enrolled in the study and 237 were eligible for analysis in each study arm. During the first six months, virological suppression was better with the LPV/r-based regimen than with the EFV-based regimen (93.80 vs 87.80% for P < 0.05). Viral suppression rates continued to increase until 12 months, remain steady thereafter until 24 months, for both groups. The multilevel analysis revealed that patients in the LPV/r group were more likely to display improvements in CD4 T-cell count over time than those in the EFV group (P < 0.001). Grade 3 or 4 laboratory adverse events were observed in 14 patients (5.91%) from the LPV/r group and three patients (1.20%) in EFV group.Conclusion: Our findings demonstrate that LPV/r-containing regimens are effective and well-tolerated in Chinese treatment-naïve patients with HIV-1 infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 10(2019) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bin Su [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adverse effects |
|---|
| doi: |
10.3389/fphar.2019.01472 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ046868666 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ046868666 | ||
| 003 | DE-627 | ||
| 005 | 20230308114550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2019.01472 |2 doi | |
| 035 | |a (DE-627)DOAJ046868666 | ||
| 035 | |a (DE-599)DOAJecb3fb25ba604eb6b37b26b94f6a1f3c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Bin Su |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Lopinavir/ritonavir (LPV/r) is a major antiretroviral treatment in China, but little is known about the performance of first-line LPV/r-based regimen in treatment-naïve patients with human immunodeficiency virus type 1 (HIV-1) infection. This study aims to assess the efficacy and adverse effect events of LPV/r plus lamivudine and tenofovir or zidovudine as an initial antiretroviral treatment in HIV-1-infected individuals for whom cannot take efavirenz (EFV) or is allergic to EFV.Methods: We performed a retrospective study of patients registering with the China’s National Free Antiretroviral Treatment Program from July 2012 to January 2017, followed at a tertiary care hospital in Beijing, China. The primary outcome was the proportion of subjects with HIV-1 RNA ≤40 copies/ml at 6 and 24 months of treatment. We assessed the immunological response and adverse events.Results: In total, 4,862 patients were enrolled in the study and 237 were eligible for analysis in each study arm. During the first six months, virological suppression was better with the LPV/r-based regimen than with the EFV-based regimen (93.80 vs 87.80% for P < 0.05). Viral suppression rates continued to increase until 12 months, remain steady thereafter until 24 months, for both groups. The multilevel analysis revealed that patients in the LPV/r group were more likely to display improvements in CD4 T-cell count over time than those in the EFV group (P < 0.001). Grade 3 or 4 laboratory adverse events were observed in 14 patients (5.91%) from the LPV/r group and three patients (1.20%) in EFV group.Conclusion: Our findings demonstrate that LPV/r-containing regimens are effective and well-tolerated in Chinese treatment-naïve patients with HIV-1 infection. | ||
| 650 | 4 | |a human immunodeficiency virus | |
| 650 | 4 | |a first-line therapy | |
| 650 | 4 | |a antiretroviral therapy | |
| 650 | 4 | |a lopinavir/ritonavir | |
| 650 | 4 | |a efavirenz | |
| 650 | 4 | |a adverse effects | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Bin Su |e verfasserin |4 aut | |
| 700 | 0 | |a Yin Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Ruifeng Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Taiyi Jiang |e verfasserin |4 aut | |
| 700 | 0 | |a Taiyi Jiang |e verfasserin |4 aut | |
| 700 | 0 | |a Hongwei Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Zaicun Li |e verfasserin |4 aut | |
| 700 | 0 | |a An Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Ying Shao |e verfasserin |4 aut | |
| 700 | 0 | |a Wei Hua |e verfasserin |4 aut | |
| 700 | 0 | |a Tong Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Tong Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Hao Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Hao Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Shenghua He |e verfasserin |4 aut | |
| 700 | 0 | |a Lili Dai |e verfasserin |4 aut | |
| 700 | 0 | |a Lijun Sun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 10(2019) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2019.01472 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ecb3fb25ba604eb6b37b26b94f6a1f3c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fphar.2019.01472/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 | ||